期刊文献+

伊普黄酮溴化物合成及其晶体结构中的Br…π超分子作用

原文传递
导出
摘要 通过伊普黄酮与溴在甲醇中反应,得到两个伊普黄酮2,3位双键加成产物:3,8-二溴-2-甲氧基-7-异丙氧基二氢异黄酮(1)和3,6-二溴-2-甲氧基-7-异丙氧基二氢异黄酮(2),1和2混合物能在乙醇溶液中共同结晶,形成两种形状的晶体:片状和柱状,两者采用镊子可人工分离.采用IR,1H NMR和单晶X射线衍射法对它们的结构进行了表征,并对反应机理进行了探讨.单晶X射线衍射结果表明,1和2均属于单斜晶系,空间群分别为P21/n和P21/c.1和2的晶胞参数分别为:1,a=1.3569(3),b=0.6706(2),c=2.0704(4)nm,β=97.50(2)°,V=1.8678(6)nm3,Z=4,Dc=1.672Mg/m3,R=0.0455,wR=0.0779,F(000)=936;2,a=1.3854(17),b=1.1215(14),c=1.3038(17)nm,β=103.71(2)°,V=1.968(4)nm3,Z=4,Dc=1.587Mg/m3,R=0.0306,wR=0.0619,F(000)=936.1和2晶体中存在的Br…π作用、氢键、芳香氢键以及芳香堆积等作用,使它们成为结构新颖的超分子化合物.1和2属于3位卤代的二氢异黄酮化合物,该类型二氢异黄酮化合物至今未见文献报道.
出处 《中国科学(B辑)》 CSCD 北大核心 2005年第2期127-136,共10页 Science in China(Series B)
基金 陕西省科学技术研究发展计划攻关项目资助(2002K11-G8(5))
  • 相关文献

参考文献23

  • 1石炳兴,梁世乐,元英进,孙命,缪方明.紫杉醇衍生物的三维定量构效关系研究[J].高等学校化学学报,2000,21(3):401-406. 被引量:16
  • 2聂晶,卢良华,孙军.预防和治疗骨质疏松症的有效药物依普黄酮[J].中国现代应用药学,2002,19(1):7-9. 被引量:22
  • 3MacDonald J C, Whitesides G M. Solid-state structures of hydrogen-bonded tapes based on cyclic secondary diamides. Chem Rev, 1994, 94(8): 2383~2420.
  • 4William O G, Barbour L J, Atwood J L. Controlling molecular self-organization: Formation of nanometer-scale spheres and tubules. Science, 1999, 285: 1049~1051.
  • 5Luque A, Sertucha J, Castillo O, et al. Crystal packing and physical properties of pyridinium tetrabromocuprate (II) complexes assembled via hydrogen bonds and aromatic stacking interactions. New J Chem, 2001(9): 1208~1214.
  • 6Kaafarani B R, Pinkerton A A, Neckers D C. High order stacking of a perfluoro 'Y-enyne'. Tetrahedron Lett, 2001, 42(46): 8137~ 8139.
  • 7Janiak C A. Critical account on π-π stacking in metal complexes with aromatic nitrogen-containing ligands. J Chem Soc Daton Trans, 2000: 3885~3896.
  • 8Hunter C A, Sanders J K. The nature of .pi.-.pi. interactions. J Am Chem Soc, 1990, 112(14): 5525~5534.
  • 9Hunter C A. Sequence-dependent DNA structure. The role of base stacking interactions. J Mol Biol, 1993, 230(3): 1025~1054.
  • 10Wang A H, Ughetto G, Quigley G J, et al. The molecular structure of a DNA-triostin A complex. Science, 1984, 225: 1115~1121.

二级参考文献25

  • 1Chinoin. Ipriflavone is an antiosteoporotic. Pharma project,Oct, 1999,10
  • 2Reginster JY, Bufalino L, Christiansen C, et al. Design for an Ipriflavone multicenter European fracture study. Calcif Tissue Int, 1997,61 (7):28
  • 3Adami S. Bufalino L, Cervetti R, et al. Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years. Osteoporosis Int, 1997;7(2): 119
  • 4Choi YK, Han IK, Yoon HK. Ipriflavone for the treatment of osteoporosis. Osteoporos Int, 1997(7) Suppl. 3,S174
  • 5Agnusdei D,Gennari C, Bufalino L. Prevention of early postmenopausal bone loss using low doses of conjugated Estrogens and the non-hormonal, bone-active drug ipriflavone. Osteoporosis Int. 1995(5) :462
  • 6Melis GB, Paoletti AM, Bartolini R, et al. Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium. Bone and Mineral, 1992(19)Suppl. S49
  • 7Shiota E. Evaluation of the drug therapy for osteoporosis by dual-energy X-ray absorptiometry. Fukuoka Igaku Zasshi.1998,89(6): 172
  • 8Gennari C, Adami S, Agnusdei D et al. Effects of chronic treatment with Iprifiavone in postmenopausal women with Iow bone mass. CalcifTissue Int. 1997,61 (7): 19.
  • 9Agnusdei D, Bufalino L. Efficacy of Iprifiavone in established Osteoporosis and long-term safety. Calcif Tissue Int, 1997,61(S uppl): S23
  • 10王丽,孔德诚.依普黄酮治疗原发性骨质症的临床研究,西安,1999第三届国际骨质疏松研讨会论文集.

共引文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部